Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy and Safety of Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Resectable Gastric Cancer

NCT06284746 is registered in ClinicalTrials.gov with Lin Chen as lead sponsor.

NCT NCT06284746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06284746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy and Safety of Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Resectable Gastric Cancer
Lead sponsor
Lin Chen
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2023
Completion date
July 30, 2025
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, her2 negative, locally advanced gastric carcinoma, safety